Opko健康 OPK 深 滬
交易中 08-13 10:17:34 美东时间
1.34
+0.020
+1.52%
華盛通- 最 高1.3488
- 今 開1.32
- 成交量 11.98万股
- 最 低 1.32
- 昨 收 1.32
- 總市值 10.63亿
- 52周最高 2.035
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 1.11
- 委 比 -11.72%
- 總股本 7.93亿
- 歷史最高 19.20
- 量 比 0.49
- 振 幅 2.18%
- 歷史最低 0.8516
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Opko Health shares are trading lower after the company reported worse-than-expected Q2 sales results.
Opko Health shares are trading lower after the company reported worse-than-expe...
08-02 00:48
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
OPKO Health reported Q2 2025 business highlights and financial results. Key achievements include advancing the Merck Epstein-Barr virus vaccine trial, progressing immuno-oncology candidates MDX2001 and MDX2004, presenting promising data for OPK-88006 in metabolic dysfunction-associated steatohepatitis (MASH), and receiving FDA approval for the 4Kscore® Test without digital rectal examination information. The company also authorized an additional ...
07-31 20:05
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
OPKO Health, Inc. (NASDAQ: OPK) plans to release its Q2 and H1 2025 financial results after U.S. markets close on July 31, 2025. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day. Participants can pre-register via a link to receive a unique access PIN or join by dialing 833-630-0584 (U.S.) or 412-317-1815 (Intl.). A webcast will also be available on OPKO’s Investor Relations page. A replay will be accessible ...
07-24 20:05
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
OPKO Health 和 Entera Bio 宣布，他们关于短肠综合征治疗的新型口服 GLP-2 类似物的研究摘要，被选中在 2025 年欧洲临床营养与代谢学会年会上展示。该疗法结合了 OPKO 的长效 GLP-2 激动剂和 Entera 的 N-Tab™ 技术，为短肠综合征患者提供更便捷的口服选择，目前唯一获批的 GLP-2 激动剂需每日注射。摘要强调了口服形式的潜在优势，如提高患者依从性及个性化治疗的可能。短肠综合征是一种罕见、可能危及生命的吸收障碍性疾病，影响约 3 万名美国和欧盟患者，市场规模庞大。OPKO 和 Entera 的合作旨在通过创新技术改善这类患者的治疗方案。
07-08 12:00
OPKO Health And Entera Bio Say New Pharmacologic And Pharmacokinetic In Vivo Data For Investigational Oral OPK-88006 Tablet Treatment Selected For Presentation At ENDO 2025 Annual Meeting
OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected
06-25 20:12
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
OPKO Health, Inc. (Nasdaq: OPK) announced its participation in the 3rd Annual Piper Sandler Obesity Symposium on June 26, 2025. Management will join a fireside discussion moderated by Edward Tentoff. Investors can register by contacting their Piper Sandler representative. OPKO is a biopharmaceutical and diagnostics company focused on large, rapidly growing markets.
06-25 15:00
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
OPKO Health和Entera Bio宣布，其研究性口服药物OPK-88006在ENLO 2025会议上展示新数据。该药结合GLP-1和胰高血糖素，设计为每日口服或每周注射，用于肥胖及相关代谢病。双方计划今年向FDA提交IND申请，并开展1期临床试验。
06-25 12:00
OPKO Health's ModeX Therapeutics Forms Scientific Advisory Board To Guide Development Of Next-Gen Multispecific Antibodies For Cancer And Immune Diseases
Will provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancerModeX's promising immunology pipeline includes first-in class
06-09 20:39
